Nearly all patients who completed at least eight weeks of hepatitis C treatment with Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) were cured of the disease, according to a new study conducted by pharmacy benefit manager Prime Therapeutics. Prime will present the data next week at the Academy of Managed Care Pharmacy’s 2017 annual meeting.
For the study, researchers reviewed data from 311 individuals who were treated with Harvoni for at least eight weeks and had results from a sustained virologic response (SVR) test sent to the pharmacy between 12 to 24 weeks after the use of Harvoni. The SVR is used to determine a patient’s response to treatment.
The researchers found that 301 of the 311 members (96.8%) had an SVR laboratory result indicating a cure.
According to a 2016 report from the IMS Institute for Healthcare Informatics, Harvoni made its U.S. debut at a list price of $94,500, but after tough negotiations with payers, its net price comes to $50,400.
Sources: Prime Therapeutics; March 21, 2017; and IMS Institute for Healthcare Informatics; September 2016.